Recommended Articles
Deals & Exits

The Mega-Merger Comeback: Consolidation Is Back, and Founders Should Read the Playbook

By Angeled · November 9, 2026 · Deals & Exits
The Mega-Merger Comeback: Consolidation Is Back, and Founders Should Read the Playbook
The Mega-Merger Comeback: Consolidation Is Back, and Founders Should Read the Playbook

A Week of Big Deals

Strategic buyers are consolidating again, and the first week of November 2026 offered three examples of how it happens. On November 6, the European Commission conditionally approved the roughly $25 billion merger of Dutch paint maker AkzoNobel and US-based Axalta Coating Systems. On November 8, Canada's Strathcona Resources agreed to acquire Greenfire Resources for C$2.7 billion to C$2.9 billion. And on November 6, InMed Pharmaceuticals completed its all-stock merger with privately held Mentari Therapeutics, a reverse merger backed by roughly $490 million in private financings.

Three deals, three industries — coatings, oil sands, biotech — and one message: after two years frozen by high rates and regulatory caution, the biggest buyers are moving again. For founders, that matters: strategic consolidation is the exit path most startups actually take.

AkzoNobel–Axalta: The Conditional Clearance

The AkzoNobel–Axalta deal is the largest and most instructive about merger regulation. Announced in November 2025 as an all-stock merger of equals, it would create one of the world's largest paint and coatings companies, with about $17 billion in combined revenue and $600 million in synergies. Axalta shareholders receive 0.6539 AkzoNobel shares for each Axalta share, leaving AkzoNobel holders with about 55%. Both sets of shareholders approved the deal on August 5, 2026.

The European Commission approved the merger on November 6, but only on condition that AkzoNobel divest its entire vehicle-refinish coatings business in the European Economic Area — the paints body shops use to repaint vehicles — including a dedicated manufacturing site, intellectual property, staff, and transitional services. The buyer must be a coatings or related-industry player, and the merger cannot close until the Commission approves it. Closing is expected in early 2027.

Strathcona–Greenfire: The Roll-Up

The Strathcona–Greenfire deal is a roll-up inside a single shareholder's portfolio. Strathcona will acquire all outstanding Greenfire shares; holders may elect 0.25 Strathcona shares — C$9.09 on the November 6 close — or C$11.00 cash per share, a 39% premium on the cash option. Including Greenfire's roughly C$550 million of net debt, the total transaction value is C$2.7 billion to C$2.9 billion.

Waterous Energy Fund holds 72% of Greenfire and 57% of Strathcona, has agreed to vote for the transaction, and will take the share option for its Greenfire holdings. The combined business will produce about 153,000 barrels per day, making it the fourth-largest SAGD operator in Canada and the only company operating across all three major oil sands deposits — Athabasca, Cold Lake, and Lloydminster. Greenfire's leadership will keep running its assets inside a new unit, SCR Central Athabasca.

InMed–Mentari: The Reverse Merger

The third deal is the most relevant to startup founders. InMed Pharmaceuticals, a Nasdaq-listed cannabinoid drug developer running low on cash — about $1.09 million at September 30, with runway only into mid-November — completed a merger with Mentari Therapeutics, a privately held biotech developing migraine-prevention therapies.

The mechanics are the classic reverse merger: the private company takes over the public listing. Pre-merger Mentari completed private financings totalling about $490 million, including $50 million in converted notes, backed by Fairmount, Blackstone Multi-Asset Investing, Wellington Management, a16z Bio + Health, and Perceptive Advisors. The funding should support development into 2029. InMed's pre-merger shareholders retain about 1.5% of the combined entity, plus contingent value rights tied to any future monetisation of the legacy assets. The company redomesticated from British Columbia to Nevada, did a 1-for-10 reverse split, and begins trading as Mentari Therapeutics (MTRI) on November 9.

Mentari's pipeline is early-stage and unproven: MT-001, an anti-PACAP antibody, targets Phase 2 data around 2028, and MT-002, a bispecific anti-PACAP and anti-CGRP antibody, should produce Phase 1 data around 2027. But the deal's real story is the structure: a private company with a promising pipeline and $490 million of fresh capital bought a public listing from a company that had run out of money. That is the reverse merger as a financing tool, and a route more founders should understand.

The M&A Playbook for Founders

Three deals, three lessons.

Carve-outs are the new deal flow. When regulators force a divestiture — as the European Commission did with AkzoNobel's vehicle-refinish business — they create a standalone company that needs a buyer, a management team, and capital. Founders who move quickly on carve-outs will find assets large buyers are forced to sell at a fair price.

Roll-ups reward the consolidator. The Strathcona deal shows how scale is built in mature industries: combine adjacent assets under one roof, cut duplicated costs, and let the larger company command a better valuation. Founders in fragmented markets should ask: consolidator or consolidated?

Exit timing is a skill. InMed sold its listing at the moment its cash ran out. Mentari bought a listing at the moment it had $490 million to deploy. The reverse merger worked because both sides' timing aligned. Founders who wait until they have no leverage get the worst terms.

The Bottom Line

The mega-merger comeback is real: a $25 billion coatings combination in Brussels, a C$2.9 billion oil sands roll-up in Calgary, and a $490 million biotech reverse merger on Nasdaq — all in one week. Consolidation creates exits — for the companies being bought, for the carve-outs being sold, and for the founders who understand the playbook. The question is whether you are positioned to ride the wave or to be rolled up by it.

Angeled.com connects founders with investors.

pymnts.com — EU Clears $25 Billion AkzoNobel-Axalta Merger With Antitrust Conditions (November 8, 2026)
monoscoops.com — European Commission conditionally approves AkzoNobel-Axalta merger (November 2026)
tradingview.com (PR Newswire) — Strathcona Resources Ltd. Announces Agreement to Acquire Greenfire Resources Ltd. (November 8, 2026)
reuters.com — Canada's Strathcona to buy Greenfire in up to $2 billion deal (November 9, 2026)
prnewswire.com — InMed Pharmaceuticals Completes Closing of Merger with Mentari Therapeutics (November 6, 2026)
dealroom.co — Cannabis firm InMed becomes migraine biotech Mentari in merger backed by $490M (November 6, 2026)

Read Next